NEW YORK — Predictive Oncology, formerly Precision Therapeutics, said today that its Helomics subsidiary has partnered with molecular imaging firm ChemImage to develop technology for monitoring how prostate cancer responds to treatment.
Under the terms of the agreement, ChemImage will provide Helomics with a set of human prostate biopsy and prostatectomy tissue samples for sequencing. Helomics will integrate the sequencing results and existing Raman spectroscopy data on the samples into its D-CHIP — or Dynamic Clinical Health Insights — artificial intelligence (AI) knowledgebase with the goal of building a predictive model of prostate cancer drug response.
Additional terms of the deal between the Pittsburgh-based companies was not disclosed.
"We believe that alliances of this kind are an excellent opportunity to demonstrate the power of the multi-omic approach coupled to AI with the goal of building predictive models for identifying and treating patients at higher risk," Helomics CTO Mark Collins said in a statement.